Europe
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.
Genomic medicine company Sangamo Therapeutics announced today that it has entered a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies for three neurodevelopmental targets, including autism spectrum disorder.
Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The drug is an investigational monoclonal antibody being developed for tauopathies like progressive supranuclear palsy (PSP) and Alzheimer’s disease.
Three months after joining forces to develop an adjuvanted vaccine for COVID-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
PRESS RELEASES